Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Champions OncologyCSBR +7.26%64 Debt-to-Equity is 1.15 as of Apr. 2026, which is at its 10-year median of 1.15. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.79 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 968 Biotechnology companies, Champions Oncology ranks worse than 88.64% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Champions Oncology's Debt-to-Equity or its related term are showing as below:
CSBR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.9 Med: 1.15 Max: 14.33
Current: 1.15
During the past 13 years, the highest Debt-to-Equity Ratio of Champions Oncology was 14.33. The lowest was -3.90. And the median was 1.15.
CSBR's Debt-to-Equity is ranked worse than 88.64% of 968
companies
in the Biotechnology industry
Industry Median: 0.16
vs CSBR: 1.15
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Champions Oncology Debt-to-Equity Related Terms
Champions Oncology Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBR vs RLYB, NRXS, VRCA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Champions Oncology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (CSBR) has a Debt-to-Equity of 1.15 as of Apr. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Champions Oncology and its competitors. This is near median its historical median of 1.15. According to the industry distribution chart, Champions Oncology ranks #858 out of 968 companies in the Biotechnology industry, placing it in the top 88.6%.
Is Champions Oncology's Debt-to-Equity too high?
Champions Oncology's current Debt-to-Equity of 1.15 is near median its 10-year median of 1.15. The Biotechnology industry median Debt-to-Equity is 0.16. Champions Oncology's value of 1.15 is 618.8% above this industry median. Based on the distribution chart, Champions Oncology ranks #858 out of 968 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Debt-to-Equity compare to RLYB and NRXS?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #858 out of 968 companies for Debt-to-Equity. This places Champions Oncology in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Champions Oncology's value of 1.15 is 618.8% above this benchmark. While the company's 10-year median is 1.15 vs. the industry median of 0.16, Champions Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Champions Oncology's current Debt-to-Equity of 1.15 is 618.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Champions Oncology and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current Debt-to-Equity is 1.15, which is near median its own 10-year median of 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.79, compared to a current price of $5.76 — trading 15.2% below its estimated fair value. The current Debt-to-Equity is 1.15, which is near median its 10-year median of 1.15 and 618.8% above the Biotechnology industry median of 0.16. Champions Oncology's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Debt-to-Equity is 1.15 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $5.76 is trading 15.2% below its estimated GF Value™ of $6.79.
GuruFocus considers Champions Oncology to be Modestly Undervalued.
Key valuation signals for CSBR:
Debt-to-Equity: 1.15 (near median its 10-year median of 1.15)
GF Value™: $6.79 vs. price of $5.76 (15.2% below fair value)
Industry Position: 618.8% above the Biotechnology median (#858 of 968)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
